Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Archives of Rheumatology|December 4, 2023
Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure databaseEmine Duygu Ersözlü, Mustafa Ekici, Belkis Nihan Coşkun, et al.
Turkish Journal of Medical Sciences|February 21, 2021
Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemicUmut Kalyoncu, Yavuz Pehlivan, Servet Akar, et al.
Clinical Rheumatology|December 21, 2005
A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritisSalih Pay, Nuran Türkçapar, Mukaddes Kalyoncu, et al.
Archives of Rheumatology|April 23, 2025
Predicting extra-musculoskeletal and peripheral manifestations and their role on biologic treatment in patients with axial spondyloarthritis: TReasure experienceElif Durak Ediboglu, Umut Kalyoncu, Dilek Solmaz, et al.
International Journal of Rheumatic Diseases|December 6, 2023
Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality ratesGüllü Sandal Uzun, Arzu Taghiyeva, İbrahim Y Çakır, et al.
Rheumatology (Oxford, England)|June 24, 2023
The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up studyBurcu Yagiz, Nihal Lermi, Belkis N Coskun, et al.
Rheumatology International|July 6, 2021
In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?Burcu Yagiz, Belkis Nihan Coskun, Yavuz Pehlivan, et al.
Clinical and Experimental Rheumatology|August 31, 2023
Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure RegistryOmer Karadag, Bayram Farisogullari, Burcu Yagiz, et al.
The Journal of Rheumatology|January 17, 2016
Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background PrevalenceBunyamin Kisacik, Omer Nuri Pamuk, Ahmet Mesut Onat, et al.
International Journal of Rheumatic Diseases|May 13, 2025
Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney DiseaseDilara Bulut Gökten, Mehmet Engin Tezcan, Burcu Yağız, et al.
Pageof 12